Karuna Therapeutics(KRTX)
Search documents
Karuna Therapeutics(KRTX) - 2021 Q3 - Quarterly Report
2021-11-04 10:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38958 Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Delaware | 2 ...
Karuna Therapeutics(KRTX) - 2021 Q2 - Quarterly Report
2021-08-05 11:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38958 Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0605902 ...
Karuna Therapeutics(KRTX) - 2021 Q1 - Quarterly Report
2021-05-06 11:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38958 Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-060590 ...
Karuna Therapeutics(KRTX) - 2020 Q4 - Annual Report
2021-02-25 12:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38958 Karuna Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-0605902 (State or other jurisdict ...
Karuna Therapeutics(KRTX) - 2020 Q3 - Quarterly Report
2020-11-05 11:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38958 Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-06 ...
Karuna Therapeutics(KRTX) - 2020 Q2 - Quarterly Report
2020-08-05 10:30
WASHINGTON, DC 20549 SECURITIES AND EXCHANGE COMMISSION UNITED STATES FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38958 Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0605902 ...
Karuna Therapeutics(KRTX) - 2020 Q1 - Quarterly Report
2020-05-07 10:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR Delaware 27-0605902 (State or other jurisdiction of incorporation or organization) 33 Arch Street, Suite 3110 Boston, Massachusetts 02110 (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) Securities registered pursuant to Section 12(b) of the ...
Karuna Therapeutics(KRTX) - 2019 Q4 - Annual Report
2020-03-24 10:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38958 Karuna Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...
Karuna Therapeutics(KRTX) - 2019 Q3 - Quarterly Report
2019-11-07 11:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 33 Arch Street, Suite 3110 Boston, Massachusetts 02110 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transi ...
Karuna Therapeutics(KRTX) - 2019 Q2 - Quarterly Report
2019-08-08 10:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38958 Karuna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0605902 ...